GlobeNewsWire
17 Aug 2026, 00:35 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Mesoblast has completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain. — Completion of treatment is a major de-risking milestone that moves the company closer to a binary clinical readout.
+0.60The company estimates the chronic low back pain indication has potential peak annual revenue exceeding US$10 billion with single-digit market penetration. — The scale of the addressable market suggests a massive valuation upside if the drug is approved.
+0.50Top-line results for the Phase 3 trial are expected in mid-CY2027. — This provides a concrete timeline for investors, though the long wait until 2027 limits immediate price action.
+0.20Continue reading
6 related stories
Search tags
Rexlemestrocel-L has received RMAT designation from the FDA, making it eligible for priority review upon BLA filing. — Regulatory designations reduce the time to market and indicate FDA interest in the therapy's potential.
+0.20Which stocks this story touches
The company achieved a major milestone by completing patient treatment in a pivotal Phase 3 trial for a potential blockbuster product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
8h ago
